Connect with us

Technology

Identiv Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Published

on

Perform-Accelerate-Transform Strategy Implementation Underway with Strengthened Commercial Team

SANTA ANA, Calif., March 5, 2025 /PRNewswire/ — Identiv, Inc. (NASDAQ: INVE), a global leader in RFID-enabled Internet of Things (IoT) solutions, today released its financial results for the fourth quarter and fiscal year ended December 31, 2024.

“The fourth quarter of 2024 marks the beginning of Identiv’s evolution into a pure play IoT solutions company,” said Identiv CEO Kirsten Newquist. “With our Perform-Accelerate-Transform strategic framework in place, we are focused on driving future growth. We are strengthening our team, adding new strategic partnerships, keeping our new product development pipeline robust, and making steady progress in the Thailand production transition. We are confident that Identiv’s capabilities and focused approach will enable us to capitalize on emerging growth opportunities and deliver meaningful returns to our shareholders.”

Financial Results for Fiscal Year 2024
Revenue for fiscal year 2024 was $26.6 million compared to $43.4 million in fiscal year 2023. Fiscal year 2024 GAAP gross margin was 1.3% and non-GAAP gross margin was 8.0%, compared to fiscal year 2023 GAAP gross margin of 13.8% and non-GAAP gross margin of 16.6%.

GAAP operating expenses, including research and development, selling and marketing, general and administrative, and restructuring and severance, were $28.3 million in fiscal year 2024, compared to $19.5 million in fiscal year 2023. Non-GAAP operating expenses were $17.9 million in fiscal year 2024, compared to $16.7 million in the fiscal year 2023. Fiscal year 2024 GAAP operating expenses included $6.2 million in strategic transaction-related costs and $3.5 million in stock-based compensation.

Fiscal year 2024 GAAP net loss from continuing operations was ($25.9) million, or ($1.14) per basic and diluted share, compared to GAAP net loss from continuing operations of ($13.9) million, or ($0.66) per basic and diluted share, in fiscal year 2023.

Non-GAAP adjusted EBITDA loss in fiscal year 2024 was ($15.8) million, compared to ($9.5) million in fiscal year 2023. 

Financial Results for Fiscal Fourth Quarter 2024
Revenue for the fourth quarter of 2024 was $6.7 million, compared to $11.3 million in the fourth quarter of 2023. Fourth quarter 2024 GAAP gross margin was (14.9%) and non-GAAP gross margin was (5.2%), compared to fourth quarter 2023 GAAP gross margin of 16.2% and non-GAAP gross margin of 19.5%. 

GAAP operating expenses, including research and development, selling and marketing, general and administrative, and restructuring and severance, were $5.6 million in the fourth quarter of 2024, compared to $5.2 million in the fourth quarter of 2023. Non-GAAP operating expenses were $4.1 million in the fourth quarter of 2024, compared to $4.1 million in the fourth quarter of 2023.

Fourth quarter 2024 GAAP net loss from continuing operations was ($4.3) million, or ($0.19) per basic and diluted share, compared to GAAP net loss from continuing operations of ($3.3) million, or ($0.16) per basic and diluted share, in the fourth quarter of 2023.

Non-GAAP adjusted EBITDA loss in the fourth quarter of 2024 was ($4.5) million, compared to ($1.9) million in the fourth quarter of 2023. 

Financial Outlook
Identiv provides guidance based on current market conditions and expectations, including macroeconomic conditions and customer demand. For fiscal Q1 2025, management currently expects net revenue to be in the range of $4.8 million to $5.1 million. 

Conference Call
Identiv management will hold a conference call today, March 5, 2025, at 5:00 p.m. EST (2:00 p.m. PST) to discuss the company’s fourth quarter and fiscal year 2024 financial results. A question-and-answer session will follow management’s presentation.

Toll-Free: 888-506-0062
International Number: +1 973-528-0011
Call ID: 652910
Webcast link: Register and Join

The teleconference replay will be available through March 19, 2025, by dialing +1 877-481-4010 (Toll-Free Replay Number) or +1 919-882-2331 (International Replay Number) and entering passcode 51938.

If you have any difficulty connecting with the teleconference, please contact Identiv Investor Relations at IR@identiv.com.

About Identiv
Identiv’s full-circle RFID-enabled IoT solutions create digital identities for physical objects, enhancing global connectivity for businesses, people, and the planet. Its solutions, integrated into over 1.5 billion applications worldwide, drive innovation across healthcare, consumer electronics, luxury goods, smart packaging, and more. For additional information, visit identiv.com.

Non-GAAP Financial Measures
This press release includes financial information that has not been prepared in accordance with accounting principles generally accepted in the United States (GAAP), including non-GAAP adjusted EBITDA, non-GAAP gross margin and non-GAAP operating expenses. Identiv uses non-GAAP financial measures internally in analyzing its financial results and believes they are useful to investors, as a supplement to GAAP measures, in evaluating ongoing operational performance. Identiv believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends. Non-GAAP gross margin excludes stock-based compensation and amortization and depreciation. Non-GAAP adjusted EBITDA excludes items that are included in GAAP net income (loss), GAAP operating expenses, and GAAP gross margin, and excludes income tax provision (benefit), net interest income (expense), net foreign currency gains (losses), stock-based compensation, amortization and depreciation, restructuring and severance, gain on investment and strategic review-related costs. Non-GAAP operating expenses exclude stock-based compensation, amortization and depreciation, strategic review-related costs, and restructuring and severance. The exclusions are detailed in the reconciliation table included in this press release. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures as detailed in this press release.

Note Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those involving future events and future results that are based on current expectations as well as the current beliefs and assumptions of management of Identiv and can be identified by words such as “anticipate,” “believe,” “continue,” “plan,” “will,” “intend,” “expect,” “outlook,” and similar references to the future. Any statement that is not a historical fact is a forward-looking statement, including statements regarding: Identiv’s expectations regarding future operating and financial outlook and performance, including 2025 first quarter guidance and outlook; Identiv’s strategy, opportunities, focus and goals; Identiv’s beliefs that its capabilities and focused approach will enable it to capitalize on emerging growth opportunities and deliver meaningful returns to shareholders; and Identiv’s expectations regarding its team, new strategic partnerships, new product development pipeline and Thailand production transition. Forward-looking statements are only predictions and are subject to a number of risks and uncertainties, many of which are outside Identiv’s control, which could cause actual results to differ materially and adversely from those expressed in any forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: Identiv’s ability to continue the momentum in its business; Identiv’s ability to successfully execute its business strategy, including, but not limited to, its capital allocation plan and organic and inorganic growth; changes in uses of capital; Identiv’s ability to capitalize on trends in its business; the effect of the change in management following the completion of the asset sale transaction; Identiv’s ability to satisfy customer demand and expectations; the level and timing of customer orders and changes/cancellations; the loss of customers, suppliers or partners; the success of Identiv’s products and strategic partnerships; changes in Identiv’s strategies and capital allocation framework; industry trends and seasonality; the impact of macroeconomic conditions and customer demand, inflation and increases in prices; and the other factors discussed in its periodic reports, including its Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Report on Form 10-Q for the quarter ended September 30, 2024  and subsequent reports filed with the Securities and Exchange Commission. All forward-looking statements are based on information available to Identiv on the date hereof, and Identiv assumes no obligation to update such statements.

Investor Relations Contact:
IR@identiv.com

Media Contact:
press@identiv.com

Identiv, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)

Three Months Ended 

Year Ended 

December 31,

December 31,

December 31,

December 31,

2024

2023

2024

2023

Net revenue

$                  6,697

$             11,348

$             26,628

$             43,445

Cost of revenue  

7,692

9,507

26,288

37,435

Gross profit 

(995)

1,841

340

6,010

Operating expenses:

Research and development 

922

1,249

3,887

4,399

Selling and marketing 

1,073

1,102

5,727

5,627

General and administrative 

3,095

2,755

18,147

9,332

Restructuring and severance

540

111

540

157

          Total operating expenses 

5,630

5,217

28,301

19,515

Loss from continuing operations 

(6,625)

(3,376)

(27,961)

(13,505)

Non-operating income (expense):

Interest income (expense), net 

1,344

(76)

1,352

(427)

Gain on investment

—

—

—

132

Foreign currency gains (losses), net 

733

177

788

(10)

Loss from continuing operations before income tax provision

(4,548)

(3,275)

(25,821)

(13,810)

Income tax (provision) benefit

271

(50)

(90)

(65)

Net loss from continuing operations

(4,277)

(3,325)

(25,911)

(13,875)

Income from discontinued operations, net of tax:

Income (loss) from Physical Security Business, net of tax

—

1,721

(2,737)

8,386

Gain on sale of Physical Security Business, net of tax

1,795

—

101,341

—

Total income from discontinued operations, net of tax

1,795

1,721

98,604

8,386

Net income (loss)

(2,482)

(1,604)

72,693

(5,489)

Cumulative dividends on Series B convertible preferred stock

(201)

(319)

(883)

(1,266)

Net income (loss) available to common stockholders

$                (2,683)

$             (1,923)

$             71,810

$             (6,755)

Net income (loss) per common share:

Basic and diluted – continuing operations

$                  (0.19)

$               (0.16)

$               (1.14)

$               (0.66)

Basic and diluted – discontinued operations

$                    0.08

$                 0.07

$                 4.18

$                 0.36

Basic and diluted – net income (loss)

$                  (0.11)

$               (0.08)

$                 3.05

$               (0.29)

Weighted average common shares outstanding: 

Basic and diluted

23,833

23,248

23,581

23,068

 

Identiv, Inc. 

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

December 31,

September 30,

December 31,

2024

2024

2023

ASSETS

Current assets:

Cash and cash equivalents

$               135,646

$               145,361

$                 23,312

Restricted cash

300

384

1,072

Accounts receivable, net of allowances

4,214

4,848

7,174

Inventories

7,475

10,710

12,649

Prepaid expenses and other current assets

2,936

4,700

2,170

Current assets held-for-sale

—

—

33,109

Total current assets

150,571

166,003

79,486

Property and equipment, net

7,694

8,203

8,472

Operating lease right-of-use assets

2,000

2,110

2,289

Other assets

686

713

678

Non-current assets held-for-sale

—

—

18,798

Total assets

$               160,951

$               177,029

$               109,723

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$                   2,746

$                   6,035

$                   5,445

Financial liabilities

—

—

9,949

Operating lease liabilities

852

880

782

Accrued compensation and related benefits

862

1,321

1,376

Accrued income taxes payable

1,173

7,180

104

Other accrued expenses and liabilities

2,179

3,595

917

Current liabilities held-for-sale

—

—

12,209

Total current liabilities

7,812

19,011

30,782

Long-term operating lease liabilities

1,167

1,251

1,507

Other long-term liabilities

29

27

26

Non-current liabilities held-for-sale

—

—

3,136

Total liabilities

9,008

20,289

35,451

Total stockholders’ equity

151,943

156,740

74,272

Total liabilities and stockholders’ equity

$               160,951

$               177,029

$               109,723

 

Identiv, Inc. 

Reconciliation of GAAP to Non-GAAP Financial Information – Continuing Operations

(in thousands)

(unaudited)

Three Months Ended 

Year Ended

December 31,

December 31,

December 31,

December 31,

2024

2023

2024

2023

Reconciliation of GAAP gross margin to non-GAAP gross margin 

GAAP gross profit

$                  (995)

$                1,841

$                    340

$                6,010

Reconciling items included in GAAP gross profit:

Stock-based compensation

3

8

20

35

Amortization and depreciation

643

361

1,773

1,184

Total reconciling items included in GAAP gross profit

646

369

1,793

1,219

Non-GAAP gross profit

$                  (349)

$                2,210

$                 2,133

$                7,229

Non-GAAP gross margin 

-5 %

19 %

8 %

17 %

Reconciliation of GAAP operating expenses to non-GAAP operating expenses

GAAP operating expenses

$                 5,630

$                5,217

$               28,301

$              19,515

Reconciling items included in GAAP operating expenses:

Stock-based compensation

(873)

(555)

(3,456)

(2,033)

Amortization and depreciation 

(52)

(37)

(206)

(169)

Strategic transaction-related costs

(55)

(435)

(6,175)

(435)

Restructuring and severance

(540)

(111)

(540)

(157)

Total reconciling items included in GAAP operating expenses

(1,520)

(1,138)

(10,377)

(2,794)

Non-GAAP operating expenses

$                 4,110

$                4,079

$               17,924

$              16,721

Reconciliation of GAAP net loss from continuing operations to non-GAAP adjusted EBITDA

GAAP net loss from continuing operations

$               (4,277)

$              (3,325)

$             (25,911)

$            (13,875)

Reconciling items included in GAAP net loss: 

Income tax provision (benefit)

(271)

50

90

65

Interest income (expense), net

(1,344)

76

(1,352)

427

Foreign currency gains (losses), net 

(733)

(177)

(788)

10

Stock-based compensation

876

563

3,476

2,068

Amortization and depreciation 

695

398

1,979

1,353

Strategic transaction-related costs

55

435

6,175

435

Gain on investment

—

—

—

(132)

Restructuring and severance

540

111

540

157

 Total reconciling items included in GAAP net loss from continuing operations

(182)

1,456

10,120

4,383

 Non-GAAP adjusted EBITDA

$               (4,459)

$              (1,869)

$             (15,791)

$              (9,492)

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/identiv-reports-fourth-quarter-and-fiscal-year-2024-financial-results-302393682.html

SOURCE Identiv

Continue Reading

Technology

Amid Rising Costs and Surgical Disruptions in ASCs, NorthStar Anesthesia Strengthens Focus on ASC Partnerships

Published

on

By

With 17 new ASC partnerships nationwide to date in 2026, NorthStar Anesthesia emphasizes proactive patient assessment, reliable staffing, and clinical consistency to help surgery centers reduce preventable cancellations and maximize surgical capacity.

IRVING, Texas, Oct. 23, 2026 /PRNewswire/ — As ambulatory surgery centers (ASCs) face mounting financial pressures, staffing challenges, and increasingly complex patient needs, anesthesia has emerged as a critical partner in their ability to operate efficiently and sustainably. NorthStar Anesthesia is addressing these challenges through a dedicated ASC model designed to reduce preventable case cancellations, improve surgical throughput, and help centers make the most of their existing operating room capacity.

NorthStar celebrates 17 new ASC partnerships nationwide to date in 2026.

“The challenge for ASCs today isn’t simply finding anesthesia coverage. It’s ensuring that coverage translates into reliable surgical capacity,” said Cindy Myers, Vice President of ASC Operations at NorthStar Anesthesia. “When cases are cancelled unnecessarily or operating rooms aren’t running as planned, the impact extends well beyond the anesthesia department. Our focus is on helping centers address those challenges systematically, so they can deliver more consistent care and operate more efficiently.”

Reducing Preventable Cancellations Through Better Preparation

One of the most significant opportunities to improve ASC performance lies in the preoperative process. When potential anesthesia concerns are not identified until the day of surgery, patients may face unexpected cancellations, surgeons lose valuable operating time, and centers absorb the cost of unused capacity.

NorthStar addresses this challenge through ASC-specific pre-anesthesia testing (PAT) guidelines and standardized clinical protocols designed to identify potential issues earlier, facilitate appropriate patient optimization, and support consistent decision-making across the surgical process.

“In ambulatory surgery, the decisions made before the patient arrives are often just as important as those made in the operating room,” said Gajan Mahendran, MD, Vice President of Physician Services at NorthStar Anesthesia. “A consistent, evidence-based approach to preoperative assessment helps us identify risks earlier, determine which patients are appropriate for the ASC setting, and address potential barriers to surgery in advance. That means fewer last-minute surprises and a better experience for patients, surgeons, and facilities.”

Aligning Anesthesia Resources With Surgical Demand

Alongside clinical challenges, ASCs are navigating a changing economic environment. In a recent Becker’s ASC Review interview, NorthStar CEO Adam Spiegel noted that approximately 80% of ASCs in NorthStar’s network now require anesthesia stipends, compared with just 10% to 15% before the pandemic.

As anesthesia costs rise, ensuring that staffing levels align with actual surgical demand has become increasingly important. NorthStar works with ASC partners to develop staffing models that reflect each facility’s case mix, surgical volume, and operating requirements. “Adding anesthesia resources doesn’t automatically improve performance if those resources aren’t aligned with the center’s surgical volume,” Myers said. “We work closely with our partners to understand their schedules, case mix, and operational needs so we can build a model that supports both reliable access to care and financial sustainability.”

Combining National Resources With Local Clinical Expertise

As ASCs take on a greater share of surgical procedures, the demands placed on anesthesia providers are becoming more complex. Smaller or locally managed anesthesia groups may face challenges maintaining consistent coverage, recruiting clinicians, or investing in standardized clinical and operational processes.

NorthStar’s model combines local clinical leadership with national recruiting capabilities, dedicated ASC operations expertise, and established quality guidelines. This infrastructure helps support continuity of care, consistent clinical practices, and the flexibility to respond to changes in surgical demand.

The approach is reflected in NorthStar’s expanding ASC partnerships.  To date in 2026 alone, NorthStar has added 17 ASC partnerships, including CarePlex Orthopaedic Ambulatory Surgery Center in Norfolk, Virginia; Stony Point Surgery Center and West Creek Surgery Center, both part of MedRVA Healthcare in Richmond, Virginia; an Orthopedic Surgery Center in Wisconsin; Eye Surgery Center of Homewood in Homewood, Alabama; and The Toledo Clinic ASC in Toledo, Ohio.

These partnerships reflect the growing importance of anesthesia providers that can address both the clinical and operational needs of outpatient surgery centers.

To learn more and to request a confidential anesthesia program assessment, please contact James Bagliani, Director of Business Development, NorthStar Anesthesia at james.bagliani@northstaranesthesia.com. 

About NorthStar Anesthesia

NorthStar Anesthesia is a company of caregivers, founded by an anesthesiologist and a Certified Registered Nurse Anesthetist (CRNA). With more than 4,000 anesthesiologists and CRNAs under its banner, NorthStar partners with more than 280 healthcare client sites across more than 20 states and counting to deliver a more productive and efficient model of anesthesia care. Its care team approach focuses on the provision of high-quality care while measurably improving operating room performance.

Media Contact: James Bagliani, Director of Business Development, NorthStar Anesthesia james.bagliani@northstaranesthesia.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/amid-rising-costs-and-surgical-disruptions-in-ascs-northstar-anesthesia-strengthens-focus-on-asc-partnerships-302918226.html

SOURCE NorthStar Anesthesia

Continue Reading

Technology

Dimethylaminopropylamine Market to Reach USD 731.9 Million by 2035 on Surfactant and Epoxy Demand, Credence Research Finds

Published

on

By

LONDON, Oct. 23, 2026 /PRNewswire/ — Credence Research Inc. has added the “Dimethylaminopropylamine Market – Growth, Share, Opportunities & Competitive Analysis, 2025–2035” study to its market intelligence portfolio. The report examines market value, segmentation, demand drivers, regional dynamics, competition and recent industry developments.

The dimethylaminopropylamine (DMAPA) market was valued at USD 452.6 million in 2025 and is projected to reach USD 731.9 million by 2035, representing a 4.92% compound annual growth rate over 2025–2035, according to Credence Research. The firm estimates 2026 revenue at USD 474.3 million. Asia Pacific accounted for the largest modeled geographic share at 44.0% in 2025, while Asia Pacific is projected to grow fastest at 5.88% annually. Market sizes, regional shares and segment shares are Credence Research estimates rather than independently audited industry totals.

Key Takeaways

The market is forecast to increase from USD 452.6 million in 2025 to USD 731.9 million by 2035, with a reported CAGR of 4.92%.Asia Pacific led the modeled 2025 geography with 44.0%; Asia Pacific has the fastest forecast geographic growth of 5.88%.By application, Surfactants accounted for 61.0% of modeled 2025 value, while Epoxy curing agents is forecast to grow at 5.66% a year.By end-use industry, Personal care and cosmetics accounted for 44.0% of modeled 2025 value, while Paints, coatings and composites is forecast to grow at 5.61% a year.The market definition excludes adjacent product or transaction value where that spending is outside the report’s measured scope.

Scope & Segmentation – Dimethylaminopropylamine Market

The study values sales of 3-(dimethylamino)-1-propylamine, an amine intermediate produced from dimethylamine and acrylonitrile. Included uses span betaine and amine-oxide surfactants, epoxy curing agents, polyurethane catalysts, water treatment chemicals, agrochemical intermediates and lubricant additives. Finished surfactants, coatings and other downstream products are excluded from the DMAPA revenue estimate.

By application: Surfactants (betaines and amine oxides); Epoxy curing agents; Polyurethane catalysts; Water treatment chemicals; Agrochemical intermediates; Fuel and lubricant additives; Others.By end-use industry: Personal care and cosmetics; Home care and institutional cleaning; Paints, coatings and composites; Water treatment; Agriculture; Automotive and lubricants.By geography: Asia Pacific; Europe; North America; Latin America; Middle East and Africa.

Read the complete report and request a sample: https://www.credenceresearch.com/report/dimethylaminopropylamine-market 

Why This Report Matters

The study distinguishes a narrowly defined revenue pool from adjacent activity that can inflate comparisons between research estimates. This helps strategy teams compare suppliers, customer budgets and product categories on a consistent basis.The base-year segment mix identifies where current purchasing is concentrated, while the modeled faster-growing categories help evaluate investment timing and market entry.Geographic shares are proprietary estimates; company and regulatory announcements are used to explain demand mechanisms, not to independently verify global market totals.

Market Overview
The study values sales of 3-(dimethylamino)-1-propylamine, an amine intermediate produced from dimethylamine and acrylonitrile. Included uses span betaine and amine-oxide surfactants, epoxy curing agents, polyurethane catalysts, water treatment chemicals, agrochemical intermediates and lubricant additives. Finished surfactants, coatings and other downstream products are excluded from the DMAPA revenue estimate.

DMAPA is a building block for cocamidopropyl betaine and related surfactants used in shampoos, body washes and dishwashing products. Producers serving consumer brands require consistent quality and supply, so the largest application tends to support repeat orders rather than episodic equipment-style purchases.

The outlook reflects expected changes in customer adoption, procurement, technology and regulation. It should be read as a modeled scenario, not as a guarantee of sales or company performance.

Key Attributes

Attribute

Details

Base year

2025

Historical reference

2018–2025

2025 market size

USD 452.6 million

2026 estimate

USD 474.3 million

2035 market forecast

USD 731.9 million

Reported CAGR

4.92% (2025–2035)

Geographic scope

Global

Primary source

https://www.credenceresearch.com/report/dimethylaminopropylamine-market

Segmentation

By application
The study divides this category into surfactants (betaines and amine oxides); epoxy curing agents; polyurethane catalysts; water treatment chemicals; agrochemical intermediates; fuel and lubricant additives; others. Surfactants led the 2025 value mix with 61.0%. Epoxy curing agents is the fastest-growing modeled subsegment at 5.66% a year. These shares represent Credence Research model outputs, not audited supplier sales.

By end-use industry
The study divides this category into personal care and cosmetics; home care and institutional cleaning; paints, coatings and composites; water treatment; agriculture; automotive and lubricants. Personal care and cosmetics led the 2025 value mix with 44.0%. Paints, coatings and composites is the fastest-growing modeled subsegment at 5.61% a year. These shares represent Credence Research model outputs, not audited supplier sales.

Market Growth Drivers

Mild cleansing formulas sustain high-volume demand
DMAPA is a building block for cocamidopropyl betaine and related surfactants used in shampoos, body washes and dishwashing products. Producers serving consumer brands require consistent quality and supply, so the largest application tends to support repeat orders rather than episodic equipment-style purchases.

Epoxy hardeners provide a faster-growth outlet
DMAPA-based amidoamines are used in epoxy curing systems for floors, protective coatings and composite applications. Wind blade production and industrial maintenance provide additional demand. The report models epoxy curing agents as the fastest-growing application, although their value starts below surfactants.

Capacity integration shapes producer economics
The chemical route depends on dimethylamine and acrylonitrile, making feedstock access and energy costs important. Integrated producers can manage these inputs and purity requirements more directly, while regional buyers value dependable supply and local technical support.

Regional Analysis
Asia Pacific held 44.0% of modeled 2025 revenue, while Asia Pacific is expected to record the fastest regional growth at 5.88%. The allocation follows the study’s defined buyer or provider-revenue scope.

Asia Pacific
Asia Pacific represented 44.0% of modeled 2025 market value. China hosts extensive betaine and epoxy manufacturing and new intermediate capacity. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

Europe
Europe represented 23.0% of modeled 2025 market value. Specialty formulations and high-purity specifications sustain demand. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

North America
North America represented 21.0% of modeled 2025 market value. Personal care, coating and water treatment buyers support a mature market. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

Latin America
Latin America represented 7.0% of modeled 2025 market value. Brazilian and Mexican cleaning and personal care production expands. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

Middle East and Africa
Middle East and Africa represented 5.0% of modeled 2025 market value. Industrial chemicals and water treatment provide emerging outlets. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

Market Challenges

Input prices and possible overcapacity
Changes in acrylonitrile and dimethylamine costs can pressure margins. New Asian capacity could also exceed near-term demand, creating price competition, especially for producers that lack integrated feedstock or differentiated purity grades.

Handling and product-purity requirements
DMAPA is a hazardous industrial intermediate requiring careful handling. Residual amines in downstream betaines can create sensitization concerns, so cosmetics customers increasingly emphasize analytical control, specifications and supplier qualification.

Future Outlook
Asia Pacific should remain the main production and demand center, with surfactants anchoring volume and epoxy applications contributing above-average growth. Supplier positioning will depend on feedstock integration, reliable logistics, high-purity grades and the pace at which new capacity is absorbed.

Competitive Landscape
BASF and Eastman Chemical are identified as integrated DMAPA producers, while Zhangjiagang Feixiang Chemical and Zhejiang Xinhua Chemical participate in Chinese production. Huntsman is relevant to downstream amine chemistry. Solvay, Evonik and Kao are better described as converters or customers for DMAPA-based surfactants rather than direct merchant DMAPA producers. No credible company-specific DMAPA revenue ranking is available.

Key Players
BASF; Eastman Chemical; Zhangjiagang Feixiang Chemical; Zhejiang Xinhua Chemical; Huntsman (downstream derivatives); Solvay (surfactants); Evonik (surfactants); Kao (surfactants)

Recent Developments

Oct. 16, 2025: BASF said the July start-up of expanded DMAPA production in Nanjing nearly doubled the site’s annual capacity and raised BASF’s global DMAPA capacity by more than 20% to approximately 85,000 metric tons.July 2025: As part of the same Nanjing project, BASF expanded polyetheramine capacity by about 25%. This is a related amine-chain investment, not an additional DMAPA plant.

Report Coverage
The study provides market estimates for 2025 and 2035, a 2026 interim estimate, analysis of the defined product and service scope, segment and geographic revenue shares, demand drivers, technology changes, competitive roles, constraints and recent dated developments. The reported CAGR and regional shares are based on Credence Research’s market model. Company announcements are contextual evidence and should not be interpreted as independent verification of the forecast.

Read the complete report and request a sample: https://www.credenceresearch.com/report/dimethylaminopropylamine-market 

Related Reports

https://www.credenceresearch.com/report/apac-infectious-enteritis-treatment-market 

https://www.credenceresearch.com/report/australia-digital-therapeutics-market 

https://www.credenceresearch.com/report/australia-corporate-education-and-upskilling-market 

https://www.credenceresearch.com/report/prescription-drugs-market 

https://www.credenceresearch.com/report/orthopedic-devices-market 

https://www.credenceresearch.com/report/parkinsons-disease-therapeutics-market 

https://www.credenceresearch.com/report/plasma-derived-therapy-market 

https://www.credenceresearch.com/report/over-the-counter-drugs-market 

https://www.credenceresearch.com/report/orphan-drugs-market 

https://www.credenceresearch.com/report/pediatric-drugs-market 

https://www.credenceresearch.com/report/pain-management-drugs-market 

https://www.credenceresearch.com/report/osteoporosis-drugs-market 

https://www.credenceresearch.com/report/patient-monitoring-devices-market 

https://www.credenceresearch.com/report/australia-drive-by-wire-market 

https://www.credenceresearch.com/report/australia-cold-chain-and-refrigerated-transport-market 

https://www.credenceresearch.com/report/australia-critical-illness-insurance-market 

https://www.credenceresearch.com/report/asia-pacific-lysosomal-acid-lipase-deficiency-lal-d-treatment-market 

https://www.credenceresearch.com/report/australia-eco-friendly-labels-market 

https://www.credenceresearch.com/report/apac-healthcare-digital-twins-market 

https://www.credenceresearch.com/report/australia-electric-vehicle-charger-operations-and-maintenance-services-market 

https://www.credenceresearch.com/report/australia-driveline-components-market 

About Us
Credence Research Inc. is a global market intelligence and consulting firm founded in 2015. It provides quantitative market research, competitive intelligence and strategic advisory services to businesses, investors and other organizations. Its research draws on primary and secondary information, industry interviews and structured market models.

The firm analyzes market size, growth drivers, segmentation, regional opportunities, supply chains and competitive positioning across industrial, technology, energy, health care and consumer markets. Its studies help clients evaluate strategic and investment decisions with documented assumptions and industry context.

Contact Us
Credence Research Inc. 
Tower C-1105, S 25, Akash Tower
Vishal Nagar, Pimple Nilakh, Haveli, Pune 411027, India 
USA: +1-888-600-6441 
sales@credenceresearch.com 
www.credenceresearch.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/dimethylaminopropylamine-market-to-reach-usd-731-9-million-by-2035-on-surfactant-and-epoxy-demand-credence-research-finds-302918151.html

Continue Reading

Technology

Misty Ventures and Aplicata Technologies Announce Strategic Partnership to Pursue Canadian Defence Opportunities

Published

on

By

Together, Aplicata and Misty Ventures will leverage their respective expertise, networks, and resources to support the commercialization of innovative technologies and help bring impactful solutions to government and public-sector markets.

SASKATOON, SK, Oct. 23, 2026 /PRNewswire-PRWeb/ — Misty Ventures, the economic development arm of Mistawasis Nêhiyawak, and Aplicata Technologies, a trusted leader in high-performance computing platforms for mission-critical defence applications, today announced they have signed a Memorandum of Understanding to explore a strategic partnership focused on pursuing and strengthening Canadian defence market opportunities.

“Partnering with Misty Ventures allows us to bring our capabilities to the Canadian defence market in a way that also creates lasting economic benefit for Mistawasis Nêhiyawak. We’re excited about the opportunity to build something meaningful together.” Mohammad Darwish, CEO of Aplicata.

Aplicata and Misty Ventures have agreed to form a Saskatchewan-based joint venture to develop and commercialize electronic warfare (EW), signals intelligence (SIGINT) and intelligence, surveillance and reconnaissance (ISR) technologies for Canadian defence.

The joint venture will deliver solutions across uncrewed aerial vehicles, aircraft, ground vehicles and naval vessels, providing the Canadian Armed Forces with a decisive operational advantage through advanced, mission-critical technology. It brings together Aplicata’s engineering, manufacturing and market expertise with Misty Ventures’ business development experience and its access to skilled talent and defence markets.

A guiding principle of the partnership is to build upon the strong business acumen, entrepreneurial capacity, and strategic vision of Mistawasis Nêhiyawak and its affiliated Indigenous communities. Through this partnership, Mistawasis Nêhiyawak seeks to leverage these strengths to contribute meaningfully to Canada’s defence priorities, supporting the development of sovereign capabilities, domestic innovation, and resilient Canadian supply chains. In addition to technology licensing, Aplicata intends to support the partnership through advanced knowledge and skills development, enabling Mistawasis Nêhiyawak to further expand its participation in Canada’s defence and security ecosystem and create lasting economic opportunity.

“This partnership reflects our commitment to building long-term, sustainable economic opportunities for Mistawasis Nêhiyawak and our broader community,” said Robert Daniels, Chief Executive Officer of Misty Ventures. “By combining our experience and market reach with Aplicata’s proven technology and market expertise, we believe we can create a defence sector business that delivers real value for Canada while creating meaningful opportunities for our people.”

“Aplicata brings a long history of innovation in advanced technologies for defence,” said Mohammad Darwish, Chief Executive Officer of Aplicata Technologies. “Partnering with Misty Ventures allows us to bring our capabilities to the Canadian defence market in a way that also creates lasting economic benefit for Mistawasis Nêhiyawak. We’re excited about the opportunity to build something meaningful together.”

About Misty Ventures

Since 2015, Misty Ventures has been the economic development entity of Mistawasis Nêhiyawak, growing through strategic partnerships across Saskatchewan’s construction, mining, oil and gas, and renewable energy sectors. Misty Ventures continues to pursue investments and collaborations aligned with its vision, mission, and values.

www.mistyventures.ca

About Aplicata Technologies

Aplicata is a trusted leader in high-performance computing platforms for mission-critical defence applications. We create innovative solutions engineered for performance and reliability, delivering results our customers can depend on. Rooted in a culture of collaboration and driven by a shared sense of purpose, we serve government and commercial organizations alike, pushing the boundaries of technology to enable new possibilities.

www.aplicata.com

Media Contact

Media Relations, Aplicata Technologies, 1 (844) 250-6300, media@aplicata.com, www.aplicata.com

View original content to download multimedia:https://www.prweb.com/releases/misty-ventures-and-aplicata-technologies-announce-strategic-partnership-to-pursue-canadian-defence-opportunities-302917752.html

SOURCE Aplicata Technologies

Continue Reading

Trending